TABLE 3.
Comparison of follow‐up antitumour therapy after tumour recurrence in patients with Hepatocellular carcinoma (HCC) who received Postoperative adjuvant transarterial chemoembolisation (PA‐TACE) or not.
| Anti‐tumour therapy | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Non‐PA‐TACE (n = 282) | PA‐TACE (n = 274) | P | Non‐PA‐TACE (n = 252) | PA‐TACE (n = 193) | P | |
| Curative treatment | 129 | 177 | < 0.001 | 111 | 139 | < 0.001 |
| Liver transplantation | 4 | 12 | 0.037 | 4 | 11 | 0.017 |
| Rehepatectomy | 10 | 18 | 0.103 | 9 | 16 | 0.032 |
| Local ablation | 115 | 147 | 0.002 | 98 | 112 | < 0.001 |
| Palliative care | 153 | 97 | < 0.001 | 141 | 54 | < 0.001 |
| TACE | 89 | 42 | < 0.001 | 84 | 19 | < 0.001 |
| Chemoradiotherapy | 15 | 8 | 0.155 | 14 | 5 | 0.125 |
| Immunotargeted therapy | 49 | 47 | 0.954 | 43 | 30 | 0.668 |
Abbreviations: HCC, Hepatocellular carcinoma; PA‐TACE, Postoperative adjuvant transarterial chemoembolisation; PSM, Propensity score matching; TACE, Transarterial chemoembolisation.